NCT06282484

Brief Summary

To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,260

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 29, 2023

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 21, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 28, 2024

Completed
Last Updated

February 28, 2024

Status Verified

February 1, 2024

Enrollment Period

9 months

First QC Date

February 21, 2024

Last Update Submit

February 21, 2024

Conditions

Keywords

gastric cancerhelicobacter pyloriprecancerous lesionGastric Xanthoma

Outcome Measures

Primary Outcomes (1)

  • corelation between the gastric xanthoma and gastric mucosa diseases

    we evaluate the corelation between the gastric xanthoma and gastric mucosa diseases according to the histopathological results and the scales the patients finished

    up to 6 months

Study Arms (3)

chronic gastritis

patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results

precancerous lesion

patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results

gastric cancer

patients with gastric cancer according to histopathological results

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing upper gastrointestinal endoscopy at Xijing Hospital

You may qualify if:

  • Age range from 18 to 75 years old, regardless of gender;
  • Endoscopic/pathological diagnosis: chronic non atrophic gastritis/chronic atrophic gastritis/intestinal metaplasia/dysplasia Hyperplasia/gastric cancer
  • Voluntarily sign an informed consent form.

You may not qualify if:

  • Previously underwent upper gastrointestinal surgery
  • Previous diagnosis of malignant tumors
  • Individuals who are unable to cooperate with the questionnaire survey due to mental disorders or other reasons
  • Those who cannot be observed by endoscopy due to acute upper gastrointestinal bleeding or other reasons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xijing Hosipital of Digestive Disease

Xi'an, Shaanxi, 710032, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Study Officials

  • Yongquan Shi, PhD

    Xijing Hosipital of Digestive Disease

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Clinical Professor

Study Record Dates

First Submitted

February 21, 2024

First Posted

February 28, 2024

Study Start

September 1, 2022

Primary Completion

June 1, 2023

Study Completion

September 29, 2023

Last Updated

February 28, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations